Ramón Salazar
Head of Medical Oncology at the Catalan Institute of Oncology (ICO), head of the Colorectal Cancer Research Group, Oncobell programme (IDIBELL) and associate professor of Medicine at the University of Barcelona
The study fulfils all the methodological and technological criteria for experimentation in preclinical models.
It explains a new mechanism of action of aspirin on the inhibition of T-lymphocyte activation, but does not influence current clinical recommendations.
The greatest limitation is the same as always in preclinical research and that is that what happens in preclinical models does not necessarily happen later in the human organism. In fact, in several randomised adjuvant trials in colon and breast cancer, aspirin has not improved relapse-free survival or overall survival.